Discussion of Phase 2 trial with LU-1... - Advanced Prostate...

Advanced Prostate Cancer

21,019 members26,196 posts

Discussion of Phase 2 trial with LU-177 PSMA-617

7 Replies

I saw this presentation of the results of a phase 2 trial with LU-177 PSMA-617 and thought it was well done. I thought this presentation could be helpful to those who are new to this or would just like to know more about the LU-177 treatment.

We'll all know a lot more about LU-177 when we get the results of the VISION trial.

urotoday.com/video-lectures...

7 Replies
Walkingwell profile image
Walkingwell

Useful, thank you.

j-o-h-n profile image
j-o-h-n

Thank you gregg...for your vision......

Good Luck, Good Health and Good Humor.

j-o-h-n Monday 05/18/2020 9:20 PM DST

Shanti1 profile image
Shanti1

Really informative video, thanks for sharing.

TheTopBanana profile image
TheTopBanana

Hello, perhaps a stupid question but what is the difference between Lu 177 and Ac 225? In terms of outcome, well anything really.

in reply to TheTopBanana

The main difference between the two is LU-177 is a beta emitter and AC-255 is an alpha emitter. Beta particles have much less mass and travel further, doing less damage to the cancer cells. Alpha particles are high energy and short range, ideal for destroying whatever cancer is in their range with double strand DNA breaks. The problem with AC-225 is that the side effects are worse because the salivary glands also put out PSMA so it goes there too. Some centers are using a combination of the two.

TheTopBanana profile image
TheTopBanana in reply to

Thank you!!

Is this something that will available eventually to hormone sensitive?

You may also like...

New Phase 1b (NON-randomized, dose timing) trial of Lu-177-PSMA-617 + Keytruda at UCSF announced

still hormone sensitive. There is a single Lu-177-PSMA-617 infusion and patients will get the...

New Trial of Lu-177-PSMA-617 to begin April 30, 2021.

multi-institutional randomized clinical trial of Lu-177-PSMA-617 that is scheduled to begin April...

177 LU-PSMA-617 Phase 3 trial starting in 2018

com/2017/10/05/endocyte-to-pursue-phase-3-trial-of-177lu-psma-617-in-metastatic-prostate-cancer/

First clinical trial of Lu-177-PSMA-617 in recurrent, hormone-sensitive men

Some early results of a pilot trial:...

VISION trial results of Lu-177-PSMA-617

ositive-result-phase-iii-study-radioligand-therapy-177lu-psma-617-patients-advanced-prostate-cancer